Transitioning to Sublocade from oral buprenorphine

Sublocade is a long-acting buprenorphine injection for moderate to severe opioid use disorder. A clinician gives it under the skin; you do not take it home or inject it yourself. It can replace the daily task of taking a buprenorphine film or tablet for some patients. The decision also depends on withdrawal risk, your response to buprenorphine, health history and whether you can return for ongoing care.

Bring the name and strength of your current product, the last dose, your usual schedule and any gaps. Describe cravings, withdrawal, sedation, substance use and previous overdoses. These details help the clinician distinguish an access problem from a treatment plan that needs to change.

The current label allows starting after a single supervised transmucosal dose when the patient tolerates it. It does not require every patient to spend seven days on daily medication first. The clinician assesses withdrawal before initiation, observes response to the first medicine and monitors symptoms after the injection before deciding that it is safe to leave.

Ask whether the evaluation and injection are separate appointments, which site will administer the medicine and who confirms delivery. Clinical approval, insurance authorization and medication arrival are separate steps. Keep a clinician-directed medication plan in place while those steps are completed.

Follow-up covers cravings, opioid use, constipation or other side effects, injection-site healing and recovery goals. Discuss counseling and practical support that would help you. Agree on a contact route for symptoms between visits and a plan for missed appointments, travel and changes in insurance.

Maintenance injections are generally monthly, but the first two visits can follow a different schedule. Tell the team early if cravings or withdrawal return. A missed injection needs a clinician plan, not a borrowed film or an extra opioid. If treatment stops, buprenorphine can remain in the body for a long time, so withdrawal and medication interactions may need monitoring for months. Discuss any wish to taper without assuming that an injection guarantees a painless end to treatment.

Ask for separate estimates for evaluation, medication, administration, testing and follow-up. Confirm the authorization period and the plan if approval or shipment is delayed. Manufacturer support has its own eligibility rules and does not establish your total clinic cost. Confirm the actual administration site before arranging time away from work; confirm that the medicine and injection visit are arranged.

Sublocade is a long-acting buprenorphine injection for moderate to severe opioid use disorder. A clinician gives it under the skin; you do not take it home or inject it yourself. It can replace the daily task of taking a buprenorphine film or tablet for some patients. The decision also depends on withdrawal risk, your response to buprenorphine, health history and whether you can return for ongoing care.

Buprenorphine partly activates opioid receptors and can reduce opioid withdrawal and cravings. The injection forms a depot that releases medicine over time. It is still an opioid medicine and can cause physical dependence. Its long action may help with medication routines, but it also means a dose cannot be quickly adjusted after an injection.

The evaluation first confirms opioid use disorder and reviews recent fentanyl, heroin, pain-pill, methadone and buprenorphine use. Some patients already taking transmucosal buprenorphine can transition directly. Patients who are new to buprenorphine need a supervised first dose and assessment of tolerability. Pregnancy, liver disease, breathing problems and sedating medicines require an individualized discussion; moderate or severe liver impairment can make this depot unsuitable.

Sublocade is for moderate to severe OUD, not an ordinary pain injection for someone who has never used opioids. The prescriber must confirm the diagnosis, opioid/buprenorphine exposure and tolerability. Opioid-naive patients are at serious risk from buprenorphine exposure and should not assume they qualify because a long-acting injection sounds convenient. Ask for an appropriate assessment rather than requesting depot treatment without the required clinical pathway.

Stopping needs an individualized plan. Long-acting buprenorphine can delay withdrawal, and some patients need months of follow-up after the last injection. Forum reports of an easy taper cannot predict your experience. Review cravings, relapse risk and ongoing support before deciding to stop.

No. Coverage approval, medication acquisition and a confirmed administration visit are separate tasks. Ask which step is complete and what remains, and request the total expected costs rather than relying on a medicine-only estimate.

Sometimes a clinician uses additional transmucosal buprenorphine during initiation to manage withdrawal. The current Sublocade label specifically allows additional transmucosal buprenorphine on induction day when needed. This does not establish a routine plan to take Suboxone with every monthly injection. Both supply buprenorphine, so extra doses require the prescribing team’s instructions. Tell them about returning withdrawal or cravings. Do not add, borrow or restart films yourself.

There is no single best option for everyone. Sublocade may suit someone who wants a provider-administered depot instead of daily buprenorphine. Suboxone film allows daily treatment and a different adjustment process. Sublocade cannot be quickly adjusted after injection and requires an administration pathway and return visits. Compare withdrawal control, previous response, side effects, pregnancy plans, access and preferences with the clinician. Methadone and naltrexone are other approved medicines for opioid use disorder. Ask how each option fits your health history, preferences and treatment access before changing care.

Both contain buprenorphine and treat opioid use disorder. Sublocade is an extended-release injection containing buprenorphine alone. A healthcare provider gives it under the skin through a restricted program. Suboxone film contains buprenorphine plus naloxone and dissolves under the tongue or inside the cheek, usually as a daily dose. They are not interchangeable products or a dose-for-dose substitution. A clinician reviews your current medicine, response and transition plan before changing treatment.

A switch may be considered, but it needs a clinician-directed transition to buprenorphine first. Sublocade is not a direct methadone replacement injection. Buprenorphine can trigger sudden withdrawal if started while another opioid’s effects are still present. The current Sublocade pathway requires tolerated transmucosal buprenorphine or established buprenorphine treatment. Ask your methadone treatment program and the receiving prescriber to coordinate the plan. Do not skip or reduce methadone, or use an online waiting-time formula, without their instructions.

Yes. Buprenorphine can precipitate sudden opioid withdrawal if started before another opioid’s effects have subsided. The clinician checks for objective withdrawal when initiating buprenorphine, confirms that a transmucosal dose is tolerated, and observes symptoms after Sublocade. Returning symptoms later or withdrawal after stopping are different problems and also need assessment. Report worsening withdrawal promptly. Do not add opioid drugs or extra buprenorphine on your own.

Yes, some people already taking transmucosal buprenorphine, including Suboxone film, can transition to Sublocade under the current label. The clinician reviews your daily dose, symptom control, missed doses, other substances and health history before choosing the first and second injections. A depot lasts much longer than a film and cannot be quickly adjusted. Bring the current package or pharmacy instructions. Do not stop films or convert the dose yourself while supply and appointment arrangements are being confirmed.